Covalon Technologies Ltd. (TSXV:COV)
2.010
-0.080 (-3.83%)
Oct 10, 2025, 3:41 PM EDT
Covalon Technologies Revenue
Covalon Technologies had revenue of 8.37M CAD in the quarter ending June 30, 2025, a decrease of -9.24%. This brings the company's revenue in the last twelve months to 32.99M, up 13.00% year-over-year. In the fiscal year ending September 30, 2024, Covalon Technologies had annual revenue of 31.17M with 17.20% growth.
Revenue (ttm)
32.99M
Revenue Growth
+13.00%
P/S Ratio
1.67
Revenue / Employee
891.67K
Employees
37
Market Cap
55.11M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2024 | 31.17M | 4.57M | 17.20% |
Sep 30, 2023 | 26.60M | 8.45M | 46.56% |
Sep 30, 2022 | 18.15M | -1.41M | -7.23% |
Sep 30, 2021 | 19.56M | 6.05M | 44.81% |
Sep 30, 2020 | 13.51M | -20.50M | -60.27% |
Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Curaleaf Holdings | 1.75B |
Green Thumb Industries | 1.57B |
dentalcorp Holdings | 1.62B |
Trulieve Cannabis | 1.62B |
Sienna Senior Living | 929.68M |
Cronos Group | 177.69M |
WELL Health Technologies | 1.12B |
Extendicare | 1.51B |
Covalon Technologies News
- 6 days ago - Empowering Nurses with Innovation: Covalon Showcases Patient Safety Solutions to Tackle Preventable Complications at ANCC National Magnet & Pathway Conference - Business Wire
- 18 days ago - Covalon Presents Evidence-Backed Innovations Making a Difference for Critically Ill Children at APHON - Business Wire
- 20 days ago - Covalon Announces Departure of Executive Chair and the Appointment of its Largest Shareholder as New Chair - Business Wire
- 25 days ago - Evidence-Driven Outcomes and Clinical Innovation Highlight Covalon's Presence at the Association for Vascular Access 2025 Annual Meeting - Business Wire
- 27 days ago - Covalon Announces Publication of Impactful VALGuard® Line Guard Clinical Study Demonstrating Significant Reduction in Central Line-Associated Blood Stream Infections (CLABSIs) - Business Wire
- 7 weeks ago - Covalon Technologies Ltd. (CVALF) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Covalon Technologies Ltd. 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 7 weeks ago - Covalon Technologies GAAP EPS of $0.00, revenue of $8.4M - Seeking Alpha